Comorbidities and Associated Conditions in Vitiligo

Conclusions

• Vitiligo is associated with a substantial burden of autoimmune comorbidity, especially thyroid disease, alopecia areata, atopic dermatitis, rheumatoid arthritis, and other connective tissue disorders.
• A positive family history and autoimmune markers can identify vitiligo patients, especially children, who are at higher risk for thyroid autoimmunity even when TSH is still normal.
• Children with vitiligo who have active or widespread disease should be monitored closely and treated early, including topical therapy and narrowband UVB or excimer laser when appropriate.
• Atopy is common in vitiligo and appears particularly linked with childhood onset and more extensive body surface area involvement.
• Vitiligo is associated with metabolic syndrome and cardiometabolic risk in adults, while pediatric risk seems to increase as patients approach adolescence.
• Vitiligo is also linked to significant mental health burden, including depression, anxiety, social phobia, and related behavioral disorders.
• ANA positivity and photosensitivity warrant careful evaluation, but may not always indicate a persistent systemic autoimmune disorder.
• 308-nm laser can still improve repigmentation in ANA-positive vitiligo, but complete repigmentation may be more difficult than in ANA-negative patients.
• Vitiligo may be bidirectionally associated with rheumatoid arthritis and osteoporosis, supporting the idea that shared immune and metabolic pathways contribute to multimorbidity.
• Vitamin D is presented as a potentially important immunomodulatory adjunct for patients with vitiligo and comorbid autoimmune risk.
• Patients with vitiligo receiving systemic immunosuppressive therapy should be considered for shingles vaccination because herpes zoster risk is elevated.
• Overall, vitiligo appears to be a multisystem inflammatory condition with clinically meaningful comorbidity risk, so screening and surveillance should be routine rather than selective.